NASDAQ:SPRY - Get Free Report ) insider Sarina Tanimoto sold 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $9.34, for a total transaction of $934,000.00. Following the transaction, the insider now directly owns 1,596,494 shares of the company's stock, valued at approximately $14,911,253.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link .
Get ARS Pharmaceuticals alerts:
Sign Up
Sarina Tanimoto also recently made the following trade(s):
On Tuesday, April 16th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.28, for a total transaction of $928,000.00. On Friday, March 22nd, Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total transaction of $21,133.86. On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.00, for a total value of $3,996.00. On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.02, for a total value of $890,977.56. On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.01, for a total value of $6,307.00. ARS Pharmaceuticals Price Performance Shares of SPRY stock traded down $0.26 on Thursday, hitting $8.80. 332,056 shares of the stock traded hands, compared to its average volume of 596,857. ARS Pharmaceuticals, Inc. has a 52 week low of $2.55 and a 52 week high of $11.27. The firm has a 50 day simple moving average of $9.05 and a two-hundred day simple moving average of $6.76. The firm has a market cap of $852.67 million, a price-to-earnings ratio of -15.44 and a beta of 0.88.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report ) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.07. Sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -0.69 EPS for the current year.
Hedge Funds Weigh In On ARS Pharmaceuticals Hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC boosted its holdings in shares of ARS Pharmaceuticals by 22,300.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company's stock valued at $31,000 after purchasing an additional 5,575 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in ARS Pharmaceuticals in the 1st quarter worth approximately $60,000. AJOVista LLC purchased a new position in shares of ARS Pharmaceuticals in the fourth quarter valued at $43,000. China Universal Asset Management Co. Ltd. lifted its position in ARS Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company's stock valued at $61,000 after purchasing an additional 8,652 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in ARS Pharmaceuticals in the first quarter worth about $119,000. Institutional investors own 68.16% of the company's stock.
Analyst Upgrades and Downgrades Several analysts recently issued reports on SPRY shares. William Blair upgraded shares of ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a research report on Tuesday, February 20th. Leerink Partnrs upgraded ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 5th. Wedbush restated an "outperform" rating and issued a $19.00 price target on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. Finally, SVB Leerink raised ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $6.00 to $18.00 in a research report on Tuesday, March 5th.
Read Our Latest Report on SPRY
ARS Pharmaceuticals Company Profile (
Get Free Report )
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ARS Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.
While ARS Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
